Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Global Alzheimer’s Disease Drugs It’s Market– Industry Trends and Forecast to 2021

Author: Rahul Kanthale
by Rahul Kanthale
Posted: Sep 24, 2018
disease drugs

Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021

Wiseguyreports.Com Adds "Alzheimer’s Disease Drugs - Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2021" To Its Research Database.

Description:

Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis

  • In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.
  • Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.
  • With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 - 2020.

Global Alzheimer’s Disease Country Wise Analysis

  • In the Alzheimer’s disease drugs market, the United States is the largest market.
  • Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.
  • China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.
  • The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.

iGATE RESEARCH report titled "Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021" is a 189 Page report with 74 Figures and 14 Tables. This report provides a comprehensive assessment of the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/1542354-global-alzheimer-s-disease-drugs-market-regional-analysis-forecast-major-deals

The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:

  1. Alzheimer’s Disease - Drugs Sales and Forecast

    1. Alzheimer’s Disease - Pipeline Drugs Sales Forecast
    2. Alzheimer’s Disease Drugs - Country Wise Market and Forecast
    3. Alzheimer’s Disease - Country Wise Prevalence and Forecast
    4. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
    5. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market
    6. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research

    8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges

The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:

  1. Exelon

    1. Razadyne/Reminyl
    2. Memary
    3. Ebixa
    4. Aricept
    5. Rivastach
    6. Namenda
    7. Nootropil

    9. Namzaric

The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:

  1. Gantenerumab

    2. Crenezumab

    3. Aducanumab

The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:

  1. United States

    1. France
    2. Germany
    3. Italy
    4. Spain
    5. United Kingdom
    6. Japan
    7. China

    9. India

List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development

  1. Phase I

    2. Phase II

    3. Phase III

The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:

  1. Strategic Alliance

    1. Licensing Agreement
    2. Collaboration Deals

    4. Mergers and Acquisitions

Get Report Complete Detail @ https://www.wiseguyreports.com/reports/1542354-global-alzheimer-s-disease-drugs-market-regional-analysis-forecast-major-deals

Table of Content

  1. Executive Summary
  2. Global Alzheimer’s Disease - Drugs Market and Prevalence Analysis

2.1 Global Alzheimer’s Disease - Drugs Market and Forecast (2010 - 2021)

2.2 Global Alzheimer’s Disease - Prevalence and Forecast (2010 - 2021)

  1. Global Alzheimer’s Disease - Country Wise Market Share and Forecast (2013 - 2021)
  2. Global Alzheimer’s Disease - Drugs Sales and Forecast To 2021

4.1 Exelon (Rivastigmine) Sales and Forecast

4.2 Razadyne/Reminyl Sales and Forecast

4.3 Memary (Memantine) Sales and Forecast

4.4 Ebixa (Memantine) Sales and Forecast

4.5 Aricept (Donepezil) Sales and Forecast

4.6 Rivastach Sales and Forecast

4.7 Namenda (Memantine) Sales and Forecast

4.8 Nootropil (Piracetam) Sales and Forecast

4.9 Namzaric (Memantine and Donepezil) Sales and Forecast

  1. Global Alzheimer’s Disease - Pipeline Drugs Analysis and Sales Forecast

5.1 Gantenerumab Drugs Analysis and Sales Forecast

5.1.1 About Gantenerumab

5.1.2 Clinical Trials

5.1.3 Gantenerumab Drugs Sales Forecast

5.2 Crenezumab Drugs Analysis and Sales Forecast

5.2.1 About Crenezumab

5.2.2 Clinical Trials

5.2.3 Crenezumab Drugs Sales Forecast

5.3 Aducanumab (BIIB037) Drugs Analysis and Sales Forecast

5.3.1 About BIIB037

5.3.2 Clinical Trials

5.3.3 Aducanumab (BIIB037) Drugs Sales Forecast

Continued………..

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

About the Author

Name: Saurabh Sinha Email: Saurabh.Sinha@Wiseguyreports.Com Company: Wise Guy Research Consultants Pvt Ltd 841 198 5042

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Rahul Kanthale

Rahul Kanthale

India

Member since: Jul 23, 2018
Published articles: 186

Related Articles